EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance

Hirotsugu Uemura, Nobuo Shinohara, Yoshihiko Tomita, Norio Nonomura, Takako Yamada, Ai Yoshida, Akira Komoto

Japanese Journal of Clinical Oncology · 2023

DOI: 10.1093/jjco/hyad034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2023. Verfasst von Hirotsugu Uemura und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Faculty of Medicine, Kindai University, Osakasayama City, Osaka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Ipilimumab, Kidney Neoplasms, Nivolumab. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ono Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nivolumab and ipilimumab combination therapy is approved in Japan for unresectable or metastatic renal cell carcinoma. Because the clinical trials supporting the approval of nivolumab and ipilimumab combination therapy included relatively few Japanese patients, post-marketing surveillance was implemented to collate further safety data for nivolumab and ipilimumab combination therapy.

Methods

Patients with unresectable or metastatic renal cell carcinoma who started nivolumab and ipilimumab combination therapy between September 2018 and December 2019 were registered in this post-marketing surveillance. The observation period was 13 weeks. Safety data included treatment-related adverse events with a particular emphasis on the gastrointestinal-related (colitis, enteritis, diarrhoea and gastrointestinal perforation) and liver-related (hepatic failure, hepatic function abnormal, hepatitis and cholangitis sclerosing) treatment-related adverse events that are listed in the risk management plan for nivolumab and ipilimumab combination therapy.

Results

Of the 203 patients registered, safety data were available for 159 (119 males/40 females) with a median age of 67 years (range 22–88). Seventy-one patients received nivolumab and ipilimumab combination therapy four times per usual clinical therapy, and 33 continued nivolumab monotherapy thereafter. Any-grade treatment-related adverse events were reported in 102 (64.2%) patients and grade ≥ 3 in 63 (39.6%). Hepatic function abnormalities (13.2%), rash (8.8%) and interstitial lung disease (7.5%) were the most common treatment-related adverse events. Five patients died following treatment-related adverse events. Gastrointestinal-related and liver-related treatment-related adverse events occurred in 10 (6.3%; four with grade ≥ 3 treatment-related adverse events) and 27 (17.0%; 19 with grade ≥ 3 treatment-related adverse events) patients, respectively.

Conclusions

This post-marketing surveillance in patients with unresectable or metastatic renal cell carcinoma revealed a safety profile for nivolumab and ipilimumab combination therapy consistent with CheckMate 214. Furthermore, no new safety concerns were identified including gastrointestinal-related and liver-related treatment-related adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellIpilimumabKidney NeoplasmsNivolumabAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultAntineoplastic Combined Chemotherapy ProtocolsEast Asian PeopleProduct Surveillance, Postmarketing

Stichwörter der Autor:innen

Japaneseipilimumabnivolumabpost-marketing product surveillancerenal cell carcinoma

Substanzen

IpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Urology, Faculty of Medicine, Kindai University, Osakasayama City, Osaka, Japan.
  • Department of Renal and Genitourinary Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
  • Department of Urology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Department of Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Patient Safety Japan, Bristol Myers Squibb K.K., Tokyo, Japan.

Förderung

  • Ono Pharmaceutical Co., Ltd.

Zitieren

APA

Uemura, H., Shinohara, N., Tomita, Y., Nonomura, N., Yamada, T., Yoshida, A., & Komoto, A. (2023). The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyad034

Vancouver

Uemura H, Shinohara N, Tomita Y, Nonomura N, Yamada T, Yoshida A, et al. The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance. Japanese Journal of Clinical Oncology. 2023. doi:10.1093/jjco/hyad034

BibTeX
@article{Uemura2023,
  author = {Uemura, Hirotsugu and Shinohara, Nobuo and Tomita, Yoshihiko and Nonomura, Norio and Yamada, Takako and Yoshida, Ai and Komoto, Akira},
  title = {The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1093/jjco/hyad034}
}
Kostenlos starten →